Publications by authors named "C Dumant"
Article Synopsis
- Infliximab (IFX) is evaluated as a second-line treatment for pediatric Crohn's disease (CD) patients who experience loss of response (LOR) or intolerance to adalimumab (ADA) after one year of therapy.
- A study involving 32 patients showed that 84.4% continued with IFX after 12 months, with 68.7% achieving corticosteroid-free clinical remission.
- Key finding indicates that absence of perianal disease at the start of IFX correlates with better remission outcomes, suggesting IFX is a viable option when ADA fails.
Outcomes of Blenderized Gastrostomy Feeding in Children at Rouen University Hospital.
Pediatric Health Med Ther
August 2022
Purpose: During the last few years, there has been an observed increase in the demand for blenderized tube feeding (BTF) in the outpatient setting among the caregivers of children suffering from chronic illnesses. This study aimed to assess the clinical and biochemical effect of BTF on children's general health and determine the psychosocial effect of this feeding type on their families.
Patients And Methods: This monocenter, retrospective study was conducted at the pediatric department of Rouen Hospital, France, and included ten children receiving a blended diet via enteral feeding tubes.
The knowledge regarding celiac disease has increased dramatically in recent years, due to the availability of accurate serologic markers. Mass screening studies have shown that the prevalence of sensitization can be as high as 1/80. The range of symptoms is wide, from the classic growth failure, denutrition and diarrhea in infancy to clinically and histologically asymptomatic sensitized subjects.
View Article and Find Full Text PDF